Disease Synopsis
Overview
Drugs and Clinical Candidates
Clinical Trials (visual)
Clinical Trials (text)
Cell Line Models
Chemistry

Breast Cancer - Overview - Disease Synopsis

Drugs & Clinical Candidates


35 drugs have received FDA approval for Breast Cancer . Abemaciclib, Anastrozole, Atezolizumab, Capecitabine, Cyclophosphamide, Denosumab, Dexrazoxane Hydrochloride, Docetaxel, Doxorubicin Hydrochloride, Epirubicin Hydrochloride, Eribulin Mesylate, Everolimus, Exemestane, Fluorouracil, Fulvestrant, Gemcitabine Hydrochloride, Goserelin Acetate, Ixabepilone, Lapatinib Ditosylate, Letrozole, Megestrol Acetate, Methotrexate Sodium, Neratinib, Olaparib, PD0332991, Paclitaxel, Pamidronate Disodium, Pertuzumab, Raloxifene Hydrochloride, Ribociclib, Tamoxifen Citrate, Thiotepa, Toremifene Citrate, Trastuzumab and Vinblastine Sulfate
564 drugs have a clinical trial registered for Breast Cancer.

Sources: cancer.gov and clinicaltrials.gov
(see details)

Clinical Trials


There are 5748 clinical trials for Breast Cancer,
3385 of which have one or more drug interventions,
2363 with no drug intervention.

Sources: cancer.gov and clinicaltrials.gov
(see details)

Cell Line Models


There are 374 Cell Line Models for Breast Cancer.

Source: COSMIC
(see details)

Chemistry


There are 22050 Compounds which have been tested in Breast Cancer , 13503 <= 500nM potency.

Source: ChEMBL
(see details)

Mappings


Please note the mappings below are based on an imperfect algorithm. If you notice any anomalies please report them to us.

The following terms have been mapped from clinicaltrials.gov mesh condition terms to Breast Cancer:
Breast Cancer Lymphedema
Breast Carcinoma In Situ
Breast Neoplasms
Breast Neoplasms, Male
Carcinoma, Ductal
Carcinoma, Ductal, Breast
Carcinoma, Intraductal, Noninfiltrating
Carcinoma, Pancreatic Ductal
Hereditary Breast and Ovarian Cancer Syndrome
Inflammatory Breast Neoplasms
Pancreatic Intraductal Neoplasms
Phyllodes Tumor
Triple Negative Breast Neoplasms
Unilateral Breast Neoplasms

The following terms have been mapped from cancer.gov to Breast Cancer:
Locally advanced or metastatic breast cancer that is HR+ or hormone receptor unknown (it is not known whether it is HR+ or hormone receptor??????negative). It is used as first-line therapy in these patients
Advanced breast cancer that has gotten worse after antiestrogen therapy.
Advanced breast cancer that has gotten worse after treatment with tamoxifen citrate
As adjuvant therapy in patients with early stage breast cancer who have a high risk that the cancer will recur (come back)
As neoadjuvant therapy (to shrink the tumor before surgery) in patients with locally advanced, inflammatory, or early stage breast cancer
Breast cancer
Breast cancer in patients receiving aromatase inhibitor therapy
Breast cancer in postmenopausal women who have any of the following types of breast cancer--Early-stage, hormone receptor??????positive (HR+) breast cancer in women who have already received other treatment
Breast cancer in postmenopausal women who have any of the following types of breast cancer--Early-stage, hormone receptor??????positive (HR+) breast cancer. It is used in women who have already received other treatment
Breast cancer in women and men. It is used:In patients whose cancer has metastasized (spread to other parts of the body)
Breast cancer in women who are at high risk for the disease
Breast cancer that has metastasized (spread to other parts of the body) and has not gotten better with other chemotherapy. It is used with paclitaxel
Breast cancer that has metastasized (spread to other parts of the body) in patients whose disease has not gotten better with other chemotherapy
Breast cancer that has metastasized (spread to other parts of the body). It is used in patients who have already been treated with an anthracycline and a taxane
Breast cancer that has metastasized (spread to other parts of the body). It is used in postmenopausal women whose cancer is estrogen receptor positive (ER+) or when it is not known if the cancer is ER+ or estrogen receptor negative (ER-)
Breast cancer that has metastasized (spread) to bone
Breast cancer that has not gotten better with other treatment
Breast cancer that has recurred (come back) or metastasized (spread to other parts of the body)
Breast cancer that is HER2 negative, has certain germline mutations in the BRCA1 or BRCA2 gene, and has metastasized (spread to other parts of the body). It is used in patients whose cancer has been treated with chemotherapy given before or after surgery or for metastatic disease
Breast cancer that is HER2 positive (HER2+). It is used in patients with:Hormone receptor-negative or high-risk cancer. It is given:As combination therapy with:Doxorubicin hydrochloride, cyclophosphamide, and either paclitaxel or docetaxel; or
Breast cancer that is HER2 positive (HER2+). It is used in adults with:Hormone receptor-negative or high-risk cancer. It is givenAs combination chemotherapy with:Doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; or
Breast cancer that is HER2 positive (HER2+). It is used:In patients with metastatic disease that has not been treated with hormone therapy or chemotherapy
Breast cancer that is HER2 positive and has metastasized (spread to other parts of the body). It is used in patients who have already been treated with trastuzumab and a taxane. It is also used in these patients if the cancer recurs (comes back) after adjuvant therapy
Breast cancer that is advanced
Breast cancer that is advanced or has metastasized (spread to other parts of the body). It is used with:Capecitabine in women with HER2 positive (HER2+) breast cancer whose disease has not gotten better with other chemotherapy
Breast cancer that is advanced. It is used as palliative treatment in premenopausal and perimenopausal women
Breast cancer that is early stage and HER2 positive. It is used as extended adjuvant therapy in patients who have already been treated with trastuzumab after surgery
Breast cancer that is early stage and estrogen receptor positive
Breast cancer that is hormone receptor positive (HR+) and HER2 negative (HER2-) and is advanced or has metastasized (spread to other parts of the body). It is used:With an aromatase inhibitor in women who have not been treated with hormone therapy
Breast cancer that is hormone receptor positive (HR+) and HER2 negative (HER2-) and is advanced or has metastasized (spread to other parts of the body).It is used with fulvestrant in women whose disease got worse after treatment with hormone therapy
Breast cancer that is hormone receptor positive (HR+) and HER2 negative (HER2-) and is advanced or has metastasized (spread to other parts of the body).It is used with fulvestrant in women whose disease has gotten worse after treatment with hormone therapy
Breast cancer that is locally advanced or has metastasized and it is not known whether the cancer is HR+ or hormone receptor negative (HR-)
Breast cancer that is locally advanced or has metastasized (spread to other parts of the body) and has not gotten better with other chemotherapy. It is also used to treat breast cancer that is node-positive and can be removed by surgery
Breast cancer that is locally advanced or has metastasized (spread to other parts of the body), is HER2 positive (HER2+) and HR+
Breast cancer that is locally advanced or has metastasized (spread to other parts of the body). It is used in patients who have not gotten better with other chemotherapy
Breast cancer that is triple negative and has the PD-L1 protein. It is used with paclitaxel albumin-stabilized nanoparticle formulation in adults whose cancer is locally advanced, metastatic, or cannot be removed by surgery.????
Breast cancer. It is also used as adjuvant therapy for breast cancer that has spread to the lymph nodes after surgery
Breast cancer. It is used after surgery in patients whose cancer has spread to the lymph nodes under the arm
Breast cancer. It is used in combination with exemestane in postmenopausal women with advanced hormone receptor??????positive (HR+) breast cancer that is also HER2 negative (HER2-) and has not gotten better after treatment with letrozole or anastrozole
Breast cancer. It is used to decrease the chance of invasive breast cancer in postmenopausal women who have a high risk for developing the disease or who have osteoporosis
Breast cancer. It is used: In postmenopausal women with hormone receptor??????positive (HR+) and HER2-negative advanced cancer that has not been treated with hormone therapy
Cardiac (heart) side effects caused by doxorubicin hydrochloride in women being treated for metastatic breast cancer. Dexrazoxane hydrochloride helps make the side effects happen less often and makes them less severe when they do occur. It is used only in women who have already received high doses of doxorubicin and continue to be treated with it. This use is approved for the Zinecard brand of dexrazoxane hydrochloride
Ductal carcinoma in situ (DCIS). It is used to decrease the chance of invasive breast cancer in patients who have had surgery and radiation therapy for DCIS
Early-stage breast cancer that has been treated with tamoxifen citrate for at least five years
Letrozole in postmenopausal women with HER2+ and hormone receptor??????positive (HR+) breast cancer who need hormone therapy